Atrogi presents dual adrenergic agonist for diabetes, obesity and steatohepatitis

Oct. 11, 2023

A team from Atrogi AB has reported the activity of ATR-127, a novel dual adrenergic agonist targeting β2- and β3-adrenoceptors (ARs), for the potential treatment of steatohepatitis, obesity and diabetes.

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

In 2025, science’s biggest story was political

BioWorld

In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...

Abstract blue human heart with red cardio pulse line and red circle

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

BioWorld

Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...

Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

BioWorld Science

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....